A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
ConditionMelanoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorZhuhai Yufan Biotechnologies Co., Ltd
About this trial
This is a Phase Ib, open-label study to determine the safety and preliminary efficacy of PRJ1-3024 in China subjects with unresectable local advanced or metastatic melanoma
Eligibility criteria
Qualifiers
Male or non-pregnant, non-lactating female subjects aged ≥18 years.
ECOG Performance Status 0~1.
Has at least 1 measurable lesion as defined by RECIST 1.1 criteria.
Life expectancy of ≥3 months, in the opinion of the Investigator.
Disqualifiers
Known symptomatic brain metastases requiring >10 mg/day of prednisolone.
Significant cardiovascular disease.
Known active HBV, HCV, AIDS-related illness.
Has received a live vaccine within 30 days.
Trial design
Treatments tested in this trial
- PRJ1-3024
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov